Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05338970 · ClinicalTrials.gov registry record · Phase 3
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
A Phase 3 study of Nonsquamous Non Small Cell Lung Cancer and Egfr L858R, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 3
- Development phase
- 586
- Enrollment target
- 20
- Study locations
NCT05338970 is a Phase 3 study of Nonsquamous Non Small Cell Lung Cancer and Egfr L858R that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 586 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT05338970, a Phase 3 study of Nonsquamous Non Small Cell Lung Cancer and Egfr L858R, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 586 participants
- Enrollment target
- 20
- Study locations
Study Summary
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.
Conditions Studied
Interventions
- DRUG Platinum-based chemotherapy
- DRUG Patritumab Deruxtecan
Study Locations (20)
California
- City of Hope - Duarte
- Moores Cancer Center at the UC San Diego Health - La Jolla
- Scripps MD Anderson Cancer Center - La Jolla
- USC Norris Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente - Vallejo Medical Center - Vallejo
- Innovative Clinical Research Institute - Whittier
New York
- Memorial Sloan Kettering Cancer Center - New York
- Montefiore Medical Center - The Bronx
Alaska
- Alaska Oncology and Hematology LLC - Anchorage
Arkansas
- Highlands Oncology - Springdale
Florida
- Sarah Cannon/Florida Cancer Specialists - FCS South - Port Charlotte
Georgia
- Emory University - Atlanta
Idaho
- St Luke's Cancer Institute - Boise
Maryland
- American Oncology Partners of Maryland - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 586 participants |
| Start Date | 2022-07-08 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05338970
The ClinicalTrials.gov registry entry for NCT05338970 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 586 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Nonsquamous Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Platinum-based chemotherapy is the first listed.
NCT05338970 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Alaska.
Frequently Asked Questions
What is clinical trial NCT05338970 about?
NCT05338970 is a clinical study titled "HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy". Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for ...
What is the current status of trial NCT05338970?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 586 participants. The study started on 2022-07-08. Estimated completion is 2026-06-30.
What conditions does trial NCT05338970 study?
This clinical trial studies the following conditions: Nonsquamous Non Small Cell Lung Cancer, Egfr L858R, EGFR Exon 19 Deletion.
What interventions are being tested in trial NCT05338970?
The interventions under investigation include: Platinum-based chemotherapy (DRUG), Patritumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT05338970?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05338970 being conducted?
This trial has 20 study locations across Alaska, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonsquamous Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.